Differential mechanisms of action of interferon-β and glatiramer acetate in MS

Neurology

Volumn 59, Issue 6, 2002, Pages 802-808

  Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYTOKINE; GADOLINIUM; GAMMA INTERFERON; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MATRIX METALLOPROTEINASE; MITOXANTRONE; MYELIN BASIC PROTEIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANTIGEN PRESENTATION; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DRUG MECHANISM; HUMAN; INFLAMMATION; MOUSE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0037167526     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.6.802     Document Type: Review

References (49)

1. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-689.
2. Bar-Or A, Enedina ML, Oliveira EML, Anderson DE, Hafler DA. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol 1999;100:252-259.
3. Martin R, Sturzebecher CS, McFarland HF. Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat Immunol 2001;2:785-788.
4. O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001;21:81-92.
5. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2001;2:1149-1165.
6. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001;56:702-708.
7. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997;94:10821-10826.
8. Hussien Y, Sanna A, Soderstrom M, Link H, Huang YM. Glatiramer acetate and interferon-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001;121:102-110.
9. Sharief MK, Semra YK, Seidi OA, Zoukos Y. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 2001;120:199-207.
10. Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 2000;55:397-404.
11. Aktas O, Ari N, Rieks M, et al. Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate. Acta Neurol Scand 2001;104:266-270.
12. Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998;50:1294-1300.
13. Lunemann JD, Aktas O, Gniadek P, Zschenderlein R, Zipp F. Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients. Neurology 2001;57: 1132-1140.
14. Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Long-term effect interferon-beta1b treatment on the spontaneous and induced expression of IL-10 and TGFbeta1 in MS patients. J Neurol Sci 2000;179:43-49.
15. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon- gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurol 1995;45:2173-2177.
16. Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001;50:349-357.
17. Furlan R, Bergami A, Lang R, et al. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J Neuroimmunol 2000;111:86-92.
18. Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induced CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest 2002;109:641-649.
19. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115:152-160.
20. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
21. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating lesions. Proc Natl Acad Sci USA 1999;96:6873-6878.
22. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103: 807-815.
23. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:502-511.
24. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997;49:1111-1116.
25. Iarlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol 2000;107:100-107.
26. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol 2001;112:174-180.
27. Stuve O, Dooley NP, Uhm JH, Antel JP, Williams G, Yong VW. Interferon-β decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40:853-863.
28. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vivo migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852.
29. Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by interferon-beta1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-1408.
30. Ozenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with interferon-beta. J Neuroimmunol 2000;108:236-243.
31. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001;50:443-451.
32. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996;64:91-100.
33. Dufour A, Corsini E, Gelati M, Massa G, Tarcic N, Slamaggi A. In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena. Ann Neurol 2000;47: 680-681.
34. Li QQ, Bever CT. Glatiramer acetate blocks interleukin-1- dependent nuclear factor-kappaB activation and RANTES expression in human U-251 MG astroglial cells. Brain Res Mol Brain Res 2001;87:48-60.
35. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1, Proc Natl Acad Sci USA 2000;97:11472-11477.
36. Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-869.
37. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-297.
38. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effects of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
39. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999;53:1397-1401.
40. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105:967-976.
41. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999;5:49-55.
42. Hauben E, Butovsky O, Nevo U, et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci 2000;20:6421-6430.
43. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189: 865-870.
44. Hammarberg H, Lidman O, Lundberg C, et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000;20:5283-5291.
45. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000;107:161-166.
46. Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000;97:7446-7451.
47. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 2001;98:3398-3403.
48. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001;57:731-733.
49. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995;61:185-193.